| Name | Title | Contact Details |
|---|
The Orb® Platform automatically syncs health data from your doctor and your apps and wearable devices so you can own it, gives you context so can understand it and helps you improve it so you can transform. For consumers and patients, the Orb® Platform is a cloud-based health management platform that syncs and stores your personal health data from multiple doctor’s offices as well as your apps and wearable devices. On your computer or mobile device, Orb provides you with instant clarity and understanding behind your data while also providing actionable insight and solutions to help improve your health. For providers, the Orb® Platform enables physicians to have more oversight and understanding of their patient populations. Orb connects with both the provider’s current lab networks and/or electronic health record systems as well as the patients` external lab networks to support providers with comprehensive insights into the patient’s lab data. The Orb® Platform also enables providers to quickly identify, contact and support at-risk patient populations. Orb Health has strategically established data connectivity to 120 laboratory networks, 30 EMR platforms, and over 150 wearable devices and apps.
MediMedia Information Technologies (MMIT) was founded to assist health plans in the printing and distribution of their formulary documents. Over the last 25 years, MMIT has expanded and strengthened its relationships throughout the industry, developed innovative technology, and capitalized on trends to become the leading provider of multichannel formulary information solutions.
E*Health Line.com, Inc. is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.
Cure Alzheimers Fund is a non-profit organization that funds targeted research with the highest probability of preventing, slowing, or reversing Alzheimers disease.